| CPAY |
Report |
Corporate Payments Organic Growth |
BEAT |
pred ~16.5% vs. cons 15.2% |
MEDIUM |
| CPAY |
Report |
Total Organic Revenue Growth |
BEAT |
pred ~11% vs. cons 10.2% |
MEDIUM |
| CPAY |
Report |
Adj. EPS (Diluted Operating) |
BEAT |
pred ~$6.85 vs. cons $6.60 |
MEDIUM |
| CPAY |
Guide |
FY 2026 Revenue (FY 2026) |
BETTER |
guide ~$5.355B vs. cons $5.301B |
MEDIUM |
| CPAY |
Guide |
FY 2026 Adj. EPS (FY 2026) |
BETTER |
guide ~$27.15 vs. cons $26.79 |
MEDIUM |
| CPAY |
Guide |
Q3 2026 Revenue (Q3 2026) |
BETTER |
guide ~$1.365B vs. cons UNVERIFIED ~$1.34B |
LOW |
| CPAY |
Guide |
Q3 2026 Adj. EPS (Q3 2026) |
BETTER |
guide ~$6.95 vs. cons UNVERIFIED ~$6.75 |
LOW |
| CPAY |
Return |
Day-1 residual (stock − beta × S&P 500) |
+8.0% |
— |
MEDIUM |
| CPAY |
Return |
5-day cumulative residual |
+5.0% (FADE) |
FADE — profit-taking from elevated pre-earnings run offsets estimate revision tailwind; H2 EPS revisions provide floor |
MEDIUM |